Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
PAR PHARMACEUTICAL, INC. v. UCB, INC. et al
Case Number:
2:11-cv-02010
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 24, 2011
Par, UCB Pharma Settle Keppra Patent Fight
UCB Pharma SA and Par Pharmaceutical Inc. on Monday settled a suit Par had filed in Pennsylvania seeking a court declaration that two UCB patents were invalid and not infringed by Par's proposed generic version of the epilepsy drug Keppra.
-
March 25, 2011
Par Sues UCB Over Generic Keppra
Par Pharmaceutical Cos. Inc. filed suit Wednesday in Pennsylvania seeking declaratory judgment that its proposed generic version of epilepsy treatment Keppra XR doesn't infringe UCB Pharma SA's patents covering the drug.